Dipropyltryptamine

Dipropyltryptamine
Clinical data
Other names	DPT; Dipropyl-T; N,N-Dipropyltryptamine; 3-(2-(Dipropylamino)ethyl)indole; "The Light"
Routes of; administration	Oral, smoking, insufflation, rectal, intramuscular injection, intravenous injection
Drug class	Serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code	None;
Legal status
Legal status	DE: NpSG (Industrial and scientific use only); UK: Class A; US: Unscheduled;
Pharmacokinetic data
Onset of action	Oral: Fast; INTooltip Intranasal administration: 10–30 minutes; Smoking: ≤2–5 min; IMTooltip Intramuscular injection: 2–15 minutes
Duration of action	Oral: 2–4 hours (but up to 12 hours at high doses); INTooltip Intranasal administration: 2–4 hours; Smoking: 20 min–2 hours; IMTooltip Intramuscular injection: ~3 hours
Identifiers
	IUPAC name N-[2-(1H-indol-3-yl)]ethyl-N-propylpropan-1-amine;
CAS Number	61-52-9 ;
PubChem CID	6091;
ChemSpider	5866 ;
UNII	S7272VWU50;
ChEMBL	ChEMBL1779153;
CompTox Dashboard (EPA)	DTXSID30209847 ;
Chemical and physical data
Formula	C16H24N2
Molar mass	244.382 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	174.5 to 178 °C (346.1 to 352.4 °F)
	SMILES CCCN(CCC)CCC1=CNC2=C1C=CC=C2;
	InChI InChI=1S/C16H24N2/c1-3-10-18(11-4-2)12-9-14-13-17-16-8-6-5-7-15(14)16/h5-8,13,17H,3-4,9-12H2,1-2H3 ; Key:BOOQTIHIKDDPRW-UHFFFAOYSA-N ;
	(verify)

Dipropyltryptamine (DPT), also known as N,N-dipropyltryptamine or as "The Light", is a psychedelic drug of the tryptamine family related to dimethyltryptamine (DMT) and diethyltryptamine (DET). It is taken orally or by other routes such as smoking, insufflation, or injection. It has a relatively short duration of 2 to 4 hours orally or insufflated and 20 minutes to 2 hours smoked.

The drug acts as a serotonin receptor modulator, including as a serotonin 5-HT_2A receptor agonist. It is a close structural homologue of DMT and DET and is a skeletal isomer of diisopropyltryptamine (DiPT). Derivatives of DPT include 4-HO-DPT and 5-MeO-DPT, among others.

DPT was first described in the literature by 1954. Its hallucinogenic effects were first described in 1966. The drug was encountered as a novel designer drug by 1968 and was reported as a possible treatment for alcoholism in 1973. DPT has never been made an explicitly controlled substance in the United States. It is the sacrament of the Temple of the True Inner Light, a New York City-based psychedelic church, which considers DPT and other psychedelics to be God.